Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remicade in Chronic Pulmonary Sarcoidosis
NCT00073437Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2003
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of infliximab in sarcoidosis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Forced Vital Capacity at 24 weeks. Started Oct 2003; status: completed.
02
Drugs
infliximab
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NCT00073437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073437.